Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Omar Hudson

Pediatric Endocrinology Melbourne, FL Medical Doctor

NPI 1043417421 CMS profile 2687

1223 Gateway Dr Ste 1G, Melbourne, FL 32901

Open in the dashboard

General payments

$3,341

76 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Omar Hudson of Melbourne, FL is reported in the CMS Open Payments database as having received $3,341 across 76 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $30 2
2023 General $265 4
2022 General $202 10
2021 General $266 14
2020 General $2,125 16
2019 General $453 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Omar Hudson
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Omar Hudson were reported at $0. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Omar Hudson Pediatric Endocrinology median Middle half National median
2019 $453 $196 $68–$845 $163
2020 $2,125 $124 $37–$722 $114
2021 $266 $134 $35–$691 $132
2022 $202 $177 $47–$726 $149
2023 $265 $236 $75–$887 $160
2024 $30 $259 $91–$979 $164
2025 $0 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $2,131 12 payments
  2. Novo Nordisk Inc $415 27 payments
  3. Sanofi-Aventis U.S. LLC $120 1 payment
  4. Ascendis Pharma, Inc. $104 5 payments
  5. IBSA Pharma Inc. $66 4 payments
  6. Xeris Pharmaceuticals, Inc. $64 3 payments
  7. TOLMAR Pharmaceuticals, Inc. $62 3 payments
  8. Zealand Pharma US, Inc. $61 3 payments
  9. Tandem Diabetes Care, Inc. $57 3 payments
  10. Medtronic MiniMed, Inc. $36 2 payments
  11. Other $224 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $1,800 1 payment
  2. Food and Beverage $1,396 72 payments
  3. Travel and Lodging $93 1 payment
  4. Education $52 2 payments
Products named General payments · program years 2019–2024
  1. LUPRON DEPOT Endocrinology $1,893 2 payments
  2. Ozempic $306 21 payments
  3. LUPRON DEPOT Endocrinology $205 8 payments
  4. TZIELD $120 1 payment
  5. SKYTROFA $104 5 payments
  6. RYBELSUS $67 5 payments
  7. Tresiba $67 5 payments
  8. Tirosint $66 4 payments
  9. GVOKE PFS $64 3 payments
  10. FENSOLVI $62 3 payments
  11. Other $501 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

76 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record